High fasting insulin concentrations may be a pivotal predictor for the severity of hepatic fibrosis beyond the glycemic status in non-alcoholic fatty liver disease patients before development of diabetes mellitus

2016 ◽  
Vol 47 (10) ◽  
pp. 983-990 ◽  
Author(s):  
Kosei Masuda ◽  
Shuhei Noguchi ◽  
Masafumi Ono ◽  
Tsunehiro Ochi ◽  
Kensuke Munekage ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Fibrosis ◽  
Fatty Liver Disease ◽  
Fasting Insulin ◽  
Glycemic Status ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Have we learnt all from Improve-It? Part I. Core results and subanalyses on the effects of ezetimibe added to statin therapy related to age, gender and selected chronic diseases (kidney disease, diabetes mellitus and non- alcoholic fatty liver disease)

2020 ◽  
Vol 18 ◽  
Author(s):  
Zlatko Fras ◽  
Dimitri P. Mikhailidis
Keyword(s):  
Diabetes Mellitus ◽  
Liver Disease ◽  
High Risk ◽  
Kidney Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Risk Patients ◽  
Very High ◽  
Alcoholic Fatty Liver Disease

: IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) was a randomized clini- cal trial (18,144 patients) that evaluated the efficacy of the combination of ezetimibe with simvastatin vs simvastatin mono- therapy in patients with acute coronary syndrome (ACS) and moderately increased low-density lipoprotein cholesterol (LDL-C) levels (of up to 2.6-3.2 mmol/L; 100-120 mg/dL). After 7 years of follow-up, combination therapy resulted in an additional LDL-C decrease [1.8 mmol/L, or 70 mg/dL, within the simvastatin (40 mg/day) monotherapy arm and 1.4 mmol/L, or 53 mg/dL for simvastatin (40 mg/day) + ezetimibe (10 mg/day)] and showed an incremental clinical benefit (composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary re- vascularization (≥30 days after randomization), or nonfatal stroke; hazard ratio (HR) of 0.936, and 95% CI 0.887-0.996, p=0.016). Therefore, for very high cardiovascular risk patients “even lower is even better” regarding LDL-C, independently of the LDL-C reducing strategy. These findings confirm ezetimibe as an option to treat very-high-risk patients who cannot achieve LDL-C targets with statin monotherapy. Additional analyses of the IMPROVE-IT (both prespecified and post-hoc) include specific very-high-risk subgroups of patients (those with previous acute events and/or coronary revascularization, older than 75 years, as well as patients with diabetes mellitus, chronic kidney disease or non-alcoholic fatty liver disease). The data from IMPROVE-IT also provide reassurance regarding longer-term safety and efficacy of the intensification of li- pid-lowering therapy in very-high-risk patients resulting in very low LDL-C levels. We comment on the results of several (sub) analyses of IMPROVE-IT.

11. Risk factors for development of diabetes mellitus in non-alcoholic fatty liver disease (NAFLD) patients

2018 ◽  
Vol 8 ◽  
pp. S39-S40
Author(s):  
Shivaram Prasad Singh ◽  
Saroj Kanta Sahu ◽  
Prasanta Kumar Parida ◽  
Sambit Kumar Behera ◽  
Suryakanta Parida ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Su1633 HUMAN ACTIVITY PROFILE IN THE CONTEXT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND TYPE II DIABETES MELLITUS (DM)

2020 ◽  
Vol 158 (6) ◽  
pp. S-1365-S-1366
Author(s):  
James M. Estep ◽  
Jillian Kallman Price ◽  
Leyla de Avila ◽  
Carey Escheik ◽  
Aybike Birerdinc ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Liver Disease ◽  
Fatty Liver ◽  
Type Ii Diabetes ◽  
Fatty Liver Disease ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Activity Profile ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Sa1055 Use of Insulin and Sulfonylurea Is Associated With Hepatic Fibrosis in Diabetic Patients With Non-Alcoholic Fatty Liver Disease

2014 ◽  
Vol 146 (5) ◽  
pp. S-948
Author(s):  
George Boon-Bee Goh ◽  
Jaividhya Dasarathy ◽  
Mangesh R. Pagadala ◽  
Aynur Unalp ◽  
Carol Hawkins ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Fibrosis ◽  
Fatty Liver Disease ◽  
Diabetic Patients ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document